Ceretec sales climbed 17% in 1993

Article

Amersham International reported that sales of its brain and white blood cell SPECT imaging agent Ceretec increased 17% in fiscal 1993 (end-March). In its annual report, the British radiopharmaceutical vendor said Ceretec had sales of £26.4 million

Amersham International reported that sales of its brain and white blood cell SPECT imaging agent Ceretec increased 17% in fiscal 1993 (end-March). In its annual report, the British radiopharmaceutical vendor said Ceretec had sales of £26.4 million last year, or about $40 million at current exchange rates.

Interest in brain imaging is growing, according to Amersham, and promising new applications for the agent include early diagnosis of Alzheimer's disase.

Technetium-labeled Ceretec has been the only brain SPECT agent available in the U.S. for several years. Sales of a competing agent, Spectamine, halted two years ago after the demise of IMP, a start-up firm set up to market the iodine-123-based agent (SCAN 6/17/92).

Ceretec will soon face increased competition from Neurolite, however, a new brain imaging agent from Du Pont Merck. Neurolite is being marketed in Europe and Japan and is nearing Food and Drug Administration approval in the U.S. Amersham acknowledged that future sales of Ceretec may be affected by increased competition, but also stated that new brain SPECT agents could help enlarge the market for neuro imaging.

Sales of Metastron, Amersham's radiopharmaceutical for the palliation of bone pain caused by cancer, totaled £14.4 million, or $22 million. The agent was launched in the U.S. in July of last year.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.